{
  "docId": "019de071-a0aa-74fc-b780-f72cc7f02158",
  "docSlug": "6af314fff9e6eaaf966098f4c73a6229",
  "documentTitle": "Mink Therapeutics | IPO Presentation Deck | 36 slides",
  "authorId": "mink-therapeutics",
  "authorName": "MiNK Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7860465,
  "pageNumber": 16,
  "pageCount": 36,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The right side shows a series of CT scan comparisons (pre-treatment vs. iNKT treated) illustrating tumor shrinkage.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/16",
  "deckHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158",
  "deckJsonHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json",
  "deckAnchorHref": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.07,
        "y": 0.6
      },
      "kind": "callout",
      "text": "Favorable safety profile: One Grade 3 AE (n=33 patients in 4 trials); No serious cytokine release or neurotoxicity observed; Up to 1 billion cells per patient, comparable to approved cell therapies",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ce1cb3a-53d1-478c-86eb-15c79c933c23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.3,
        "x": 0.65,
        "y": 0.15
      },
      "kind": "image",
      "text": "CT scan comparison images showing tumor reduction",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d155b546-0971-4e32-82ef-32be649cbfcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.07,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Yamasaki et al. 2011, Takami et al 2018, Exley et al 2017. 1. 2x10^8 iNKT cells dosed in the trial depicted in the graphic on the right",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dccc7c8-ea2b-467f-960f-98ca449ae5f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.07,
        "y": 0.215
      },
      "kind": "table",
      "text": "Cancer Type: Head and Neck Cancer (SCCHN), Clinical Outcomes: ORR: 50%; Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Clinical Outcomes: SD: 67% (4/6)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ec39e8b-8c03-465b-a6be-445ed0e6b333",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.05
      },
      "kind": "title",
      "text": "Autologous iNKTs Show Benefit in Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdbd9983-8336-487d-936a-b9524d00d0e3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "98327497-c36e-41ae-9987-5cd1b6712da5",
      "evidence": "table/data: Cancer Type: Head and Neck Cancer (SCCHN), Clinical Outcomes: ORR: 50%; Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Clinical Outcomes: SD: 67% (4/6)",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 36,
      "from": 5,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b",
      "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.",
      "position": 0,
      "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 34,
      "from": 14,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c",
      "evidence": "The document outlines multiple near-term milestones and clinical readouts.",
      "position": 1,
      "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}